Vaxcyte (PCVX), a vaccine developer, jumped 30% after positive Phase 3 results. Its pneumococcal vaccine produced immune responses comparable with Pfizer’s Prevnar 20. The trial covered adults aged 50 and older.
Join our Mailing list!
Sign up to get all the latest financial news and business updates.
Please fill in the form and we will get in touch with you shortly and help answer any questions you may have about Offshore Supporting services.
